<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03302091</url>
  </required_header>
  <id_info>
    <org_study_id>1386-0002</org_study_id>
    <secondary_id>2017-002180-18</secondary_id>
    <nct_id>NCT03302091</nct_id>
  </id_info>
  <brief_title>This Study Tests How BI 1467335 is Taken up in the Body of People With Normal Kidney Function and People With Reduced Kidney Function. The Study Also Looks at How Well the Participants Tolerate BI 1467335</brief_title>
  <official_title>Pharmacokinetics, Safety and Tolerability After Multiple Dose Administration of BI 1467335 in Subjects With Moderate Renal Impairment and Subjects With Normal Renal Function (a Mono-centric, Open-label Study in Matched-group Design)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boehringer Ingelheim</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of the current study is to investigate the influence of moderate renal
      impairment on the pharmacokinetics of multiple doses in comparison to a matched control group
      with normal renal function.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 17, 2017</start_date>
  <completion_date type="Anticipated">August 3, 2018</completion_date>
  <primary_completion_date type="Anticipated">August 3, 2018</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>AUC0-24 (area under the concentration-time curve of the analyte in plasma over the time interval from 0 to 24 hours after administration of the first dose)</measure>
    <time_frame>up to 24 hours</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Cmax (maximum measured concentration of the analyte in plasma after administration of the first dose)</measure>
    <time_frame>up to 72 hours</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>AUCtau,28 (area under the concentration-time curve of the analyte in plasma over the dosing interval after administration of the 28th dose)</measure>
    <time_frame>up to 816 hours</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Cmax,28 (maximum measured concentration of the analyte in plasma following administration of the 28th dose)</measure>
    <time_frame>up to 816 hours</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>AUCtau14 (area under the concentration-time curve of the analyte in plasma over the dosing interval after administration of the 14th dose)</measure>
    <time_frame>up to 336 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cmax,14 (maximum measured concentration of the analyte in plasma following administration of the 14th dose)</measure>
    <time_frame>up to 336 hours</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Renal Insufficiency</condition>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>All Subjects</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BI 1467335</intervention_name>
    <description>28 day treatment period</description>
    <arm_group_label>All Subjects</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Despite of moderate renal impairment (Group 1) healthy male or female subjects
             according to the assessment of the investigator, based on a complete medical history
             including a physical examination, vital signs (Blood pressure (BP), Pulse rate (PR)),
             12-lead Electrocardiogram (ECG), and clinical laboratory tests

          -  Estimated glomerular filtration rate (eGFR) based on CKD-EPI formula for Group 1
             between 30 and 59 mL/min/1.73m2 and for Group 2 ≥ 90 mL/min/1.73m2

          -  Age of 18 to 79 years (incl.)

          -  BMI of 18.5 to 34 kg/m2 (incl.)

          -  Signed and dated written informed consent prior to admission to the study in
             accordance with Good Clinical Practice (GCP) and local legislation

          -  Male subjects, or female subjects who meet any of the following criteria (according to
             the CTFG Recommendations related to contraception and pregnancy testing in clinical
             trials, methods with a failure rate of less than 1% per year) starting from at least
             30 days before the first administration of trial medication and until 30 days after
             trial completion, e.g.:

               -  Use of adequate contraception, e.g. any of the following methods plus condom:
                  implants, injectables, combined oral or vaginal contraceptives (inhibition of
                  ovulation)

               -  Hormonal intrauterine device

               -  Sexually abstinent (defined as refraining from heterosexual intercourse during
                  the entire period of risk)

               -  A vasectomised sexual partner (provided that vasectomy was performed at least 1
                  year prior to enrolment and the vasectomised partner has received medical
                  assessment of the surgical success)

               -  Surgically sterilised (including bilateral tubal occlusion, hysterectomy)

               -  Postmenopausal, defined as at least 1 year of spontaneous amenorrhea (in
                  questionable cases a blood sample with simultaneous levels of FSH above 40 U/L
                  and estradiol below 30 ng/L is confirmatory)

        Exclusion Criteria:

        Healthy subjects

          -  Any finding in the medical examination (including BP, PR or ECG) is deviating from
             normal and judged as clinically relevant by the investigator

          -  Repeated measurement of systolic blood pressure outside the range of 90 to 140 mmHg,
             diastolic blood pressure outside the range of 50 to 90 mmHg, or pulse rate outside the
             range of 50 to 90 bpm

          -  Any laboratory value outside the reference range that the investigator considers to be
             of clinical relevance

          -  Any evidence of a concomitant disease judged as clinically relevant by the
             investigator

          -  Gastrointestinal, hepatic, renal, respiratory, cardiovascular, metabolic,
             immunological or hormonal disorders

          -  Estimated glomerular filtration rate (eGFR) calculated by CKD-EPI formula &lt; 90
             mL/min/1.73m2

        Subjects with moderate renal impairment

          -  Subject with significant diseases other than moderate renal impairment. A significant
             disease is defined as a disease which in the opinion of the investigator:

               -  puts the subjects at risk because of participation in the study

               -  may influence the results of the study

               -  may influence the subject's ability to participate in the study

               -  is not in a stable condition Diabetic or hypertensive subjects can be entered in
                  this trial if the disease is not significant according to these criteria.

          -  Any finding of the medical examination (including BP, PR and ECG) of clinical
             relevance

          -  Moderate and severe concurrent liver function impairment (e.g. due to hepatorenal
             syndrome) or biliary obstruction

          -  Clinically relevant laboratory abnormalities (except for renal function tests or
             deviation of clinical laboratory values that are related to renal impairment)

          -  eGFR calculated by CKD-EPI formula ≥ 60 mL/min/1.73m2 and &lt; 30 mL/min/1.73m2

        For all subjects

          -  Cholecystectomy and/or surgery of the gastrointestinal tract that could interfere with
             the pharmacokinetics of the trial medication (except appendectomy and simple hernia
             repair)

          -  Diseases of the central nervous system (including but not limited to any kind of
             seizures or stroke), and other relevant neurological or psychiatric disorders

          -  History of relevant orthostatic hypotension, fainting spells, or blackouts

          -  Chronic or relevant acute infections

          -  History of relevant allergy or hypersensitivity (including allergy to the trial
             medication or its excipients)

          -  Use of drugs within 30 days prior to administration of trial medication if that might
             reasonably influence the results of the trial (incl. QT/QTc interval prolongation)

          -  Participation in another trial where an investigational drug has been administered
             within 30 days prior to planned administration of trial medication or longer if
             required by local regulation, or within 5-half-lives of the investigational agent
             taken (whichever is longer), or current participation in another trial involving
             administration of investigational drug

          -  Smoker (more than 10 cigarettes or 3 cigars or 3 pipes per day)

          -  Inability to refrain from smoking on specified trial days

          -  Alcohol abuse (consumption of more than 20 g per day for females and 30 g per day for
             males)

          -  Drug abuse or positive drug screening

          -  Blood donation of more than 100 mL within 30 days prior to administration of trial
             medication or intended donation during the trial

          -  Intention to perform excessive physical activities within one week prior to
             administration of trial medication or during the trial

          -  Inability to comply with dietary regimen of trial site

          -  A marked baseline prolongation of QT/QTc interval (such as QTc intervals that are
             repeatedly greater than 450 ms in males or repeatedly greater than 470 ms in females)
             or any other relevant ECG finding at screening

          -  A history of additional risk factors for Torsades de Pointes (such as heart failure,
             hypokalemia, or family history of Long QT Syndrome)

          -  Subject is assessed as unsuitable for inclusion by the investigator, for instance,
             because considered not able to understand and comply with study requirements, or has a
             condition that would not allow safe participation in the study

        Female subjects will not be allowed to participate if any of the following applies:

          -  Positive pregnancy test, pregnancy or plans to become pregnant within 30 days after
             study completion

          -  Lactation period

        Male subjects will not be allowed to participate if any of the following applies:

        - Male subjects with WOCBP partner who are unwilling to use male contraception (condom or
        sexual abstinence) from the first administration of trial medication until 30 days after
        last administration of trial medication
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>79 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Boehringer Ingelheim</last_name>
    <phone>1-800-243-0127</phone>
    <email>clintriage.rdg@boehringer-ingelheim.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>CRS Clinical Research Services Kiel GmbH</name>
      <address>
        <city>Kiel</city>
        <zip>24105</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Atef Halabi</last_name>
      <phone>+49 (431) 8999801</phone>
      <email>atef.halabi@crs-group.de</email>
    </contact>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 29, 2017</study_first_submitted>
  <study_first_submitted_qc>October 2, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">October 4, 2017</study_first_posted>
  <last_update_submitted>May 2, 2018</last_update_submitted>
  <last_update_submitted_qc>May 2, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 3, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Renal Insufficiency</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

